Pleiotropic functions of EAPII/TTRAP/TDP2: Cancer development, chemoresistance and beyond

Cell Cycle

Volumn 10, Issue 19, 2011, Pages 3274-3283

  Li, Chunyang ^a   Sun, Shi Yong ^a   Khuri, Fadlo R ^a   Li, Runzhao ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer development; Chemoresistance; DNA repair; EAPII; Signal transduction; Transcription regulation

Indexed keywords

CD30 LIGAND; CD40 LIGAND; DAXX PROTEIN; ETS 1 ASSOCIATED PROTEIN II; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE 8; INTERLEUKIN 19; INTERLEUKIN 24; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN MDM2; PROTEIN MYB; SMAD3 PROTEIN; SUMO 1 PROTEIN; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR HOXA9; TRANSFORMING GROWTH FACTOR BETA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; DNA REPAIR; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 80053444953     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.19.17763     Document Type: Review

References (120)

1. Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem 2008; 8:1095-105; PMID:18855726; DOI:10.2174/138955708785909934.
2. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41:2462-78; PMID:16213704.
3. Pei H, Li C, Adereth Y, Hsu T, Watson DK, Li R. Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis. Cancer Res 2005; 65:7205-13; PMID:16103071; DOI:10.1158/0008-5472.CAN-04-3566.
4. Pei H, Yordy JS, Leng Q, Zhao Q, Watson DK, Li R. EAPII interacts with ETS1 and modulates its transcriptional function. Oncogene 2003; 22:2699-709; PMID:12743594; DOI:10.1038/sj.onc.1206374.
5. Pype S, Declercq W, Ibrahimi A, Michiels C, van Rietschoten JG, Dewulf N, et al. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappaB activation. J Biol Chem 2000; 275:18586-93; PMID:10764746; DOI:10.1074/jbc.M000531200.
6. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009; 461:674-8; PMID:19794497; DOI:10.1038/nature08444.
7. Londin ER, Meng H, Gruen JR. A transcription map of the 6p22.3 reading disability locus identifying candidate genes. BMC Genomics 2003; 4:25; PMID:12834540; DOI:10.1186/1471-2164-4-25.
8. Li C, Fan S, Owonikoko TK, Khuri FR, Sun SY, Li R. Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 2011; 30:3802-12; PMID:21478903; DOI:10.1038/onc.2011.94.
9. Rodrigues-Lima F, Josephs M, Katan M, Cassinat B. Sequence analysis identifies TTRAP, a protein that associates with CD40 and TNF receptor-associated factors, as a member of a superfamily of divalent cation- dependent phosphodiesterases. Biochem Biophys Res Commun 2001; 285:1274-9; PMID:11478795; DOI:10.1006/bbrc.2001.5328.
10. Demple B, Sung JS. Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst) 2005; 4:1442-9; PMID:16199212; DOI:10.1016/j.dnarep.2005.09.004.
11. Xanthoudakis S, Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J 1992; 11:653- 65; PMID:1537340.
12. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 2009; 11:601-20; PMID:18976116; DOI:10.1089/ars.2008.2194.
13. Tsujishita Y, Guo S, Stolz LE, York JD, Hurley JH. Specificity determinants in phosphoinositide dephosphorylation: crystal structure of an archetypal inositol polyphosphate-5-phosphatase. Cell 2001; 105:379-89; PMID:11348594; DOI:10.1016/S0092-8674(01)00326-9.
14. Mol CD, Izumi T, Mitra S, Tainer JA. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination. Nature 2000; 403:451-6; PMID:10667800; DOI:10.1038/35000249.
15. Whisstock JC, Romero S, Gurung R, Nandurkar H, Ooms LM, Bottomley SP, et al. The inositol polyphosphate-5-phosphatases and the apurinic/apyrimidinic base excision repair endonucleases share a common mechanism for catalysis. J Biol Chem 2000; 275:37055-61; PMID:10962003; DOI:10.1074/jbc. M006244200.
16. Mol CD, Kuo CF, Thayer MM, Cunningham RP, Tainer JA. Structure and function of the multifunctional DNA-repair enzyme exonuclease III. Nature 1995; 374:381-6; PMID:7885481; DOI:10.1038/374381a0.
17. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009; 461:674-8; PMID:19794497; DOI:10.1038/nature08444.
18. Grabbe C, Dikic I. Functional roles of ubiquitin-like domain (ULD) and ubiquitin-binding domain (UBD) containing proteins. Chem Rev 2009; 109:1481-94; PMID:19253967; DOI:10.1021/cr800413p.
19. Esguerra CV, Nelles L, Vermeire L, Ibrahimi A, Crawford AD, Derua R, et al. Ttrap is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination. Development 2007; 134:4381-93; PMID:18039968; DOI:10.1242/dev.000026.
20. Turner DP, Findlay VJ, Moussa O, Watson DK. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 2007; 102:549-59; PMID:17661355; DOI:10.1002/jcb.21494.
21. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-21; PMID:14557817; DOI:10.1038/nrc1208.
22. Kaminska B, Wesolowska A, Danilkiewicz M. TGFbeta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005; 52:329-37; PMID:15990918.
23. Xu J, Lamouille S, Derynck R. TGFbeta-induced epithelial to mesenchymal transition. Cell Res 2009; 19:156-72; PMID:19153598; DOI:10.1038/cr.2009.5.
24. Wang BY, Xu GL, Zhou CH, Tian L, Xue JL, Chen JZ, et al. PhiC31 integrase interacts with TTRAP and inhibits NFkappaB activation. Mol Biol Rep 2010; 37:2809-16; PMID:19757154; DOI:10.1007/s11033- 009-9829-3.
25. Li R, Pei H, Watson DK. Regulation of Ets function by protein-protein interactions. Oncogene 2000; 19:6514-23; PMID:11175367; DOI:10.1038/sj.onc. 1204035.
26. Babayeva ND, Wilder PJ, Shiina M, Mino K, Desler M, Ogata K, et al. Structural basis of Ets1 cooperative binding to palindromic sequences on stromelysin- 1 promoter DNA. Cell Cycle 2010; 9:3054-62; PMID:20686355; DOI:10.4161/cc.9.14.12257.
27. Li R, Pei H, Watson DK, Papas TS. EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene 2000; 19:745-53; PMID:10698492; DOI:10.1038/sj.onc.1203385.
28. Wang Y, Zhang P, Liu Y, Cheng G. TRAF-mediated regulation of immune and inflammatory responses. Sci China Life Sci 2010; 53:159-68; PMID:20596822; DOI:10.1007/s11427-010-0050-3.
29. Lee NK, Lee SY. Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol 2002; 35:61-6; PMID:16248971; DOI:10.5483/BMBRep.2002.35.1.061.
30. Bradley JR, Pober JS. Tumor necrosis factor receptorassociated factors (TRAFs). Oncogene 2001; 20:6482-91; PMID:11607847; DOI:10.1038/sj.onc.1204788.
31. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115:679-88; PMID:11865024.
32. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1:497-514; PMID:21165163.
33. Zucchelli S, Vilotti S, Calligaris R, Lavina ZS, Biagioli M, Foti R, et al. Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations. Cell Death Differ 2009; 16:428-38; PMID:19023331; DOI:10.1038/cdd.2008.169.
34. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9:327-37; PMID:19377505; DOI:10.1038/nrc2608.
35. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009; 37:738-48; PMID:19042970; DOI:10.1093/nar/gkn937.
36. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci USA 2001; 98:12009-14; PMID:11572945; DOI:10.1073/ pnas.211429198.
37. Yang J, Qiu L, Wang L, Huang M, Zhang H, Song LA. TRAF and TNF receptor-associated protein (TTRAP) in mollusk with endonuclease activity. Dev Comp Immunol 2011; 35:827-34; PMID:21440568; DOI:10.1016/j.dci.2011.02.013.
38. Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Nucleic Acids Res 2003; 31:4373-84; PMID:12888496; DOI:10.1093/nar/gkg497.
39. Connelly JC, Leach DR. Repair of DNA covalently linked to protein. Mol Cell 2004; 13:307-16; PMID:14967139; DOI:10.1016/S1097-2765(04)00056-5.
40. Hartsuiker E, Neale MJ, Carr AM. Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA. Mol Cell 2009; 33:117-23; PMID:19150433; DOI:10.1016/j.molcel. 2008.11.021.
41. Zeng Z, Cortes-Ledesma F, El Khamisy SF, Caldecott KW. TDP2/TTRAP is the major 5′-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J Biol Chem 2011; 286:403-9; PMID:21030584; DOI:10.1074/jbc.M110.181016.
42. Lee BH, Yoshimatsu K, Maeda A, Ochiai K, Morimatsu M, Araki K, et al. Association of the nucleocapsid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. Virus Res 2003; 98:83-91; PMID:14609633; DOI:10.1016/j. virusres.2003.09.001.
43. Zhang JQ, Wang JJ, Li WJ, Huang L, Tian L, Xue JL, et al. Cellular protein TTRAP interacts with HIV-1 integrase to facilitate viral integration. Biochem Biophys Res Commun 2009; 387:256-60; PMID:19580783; DOI:10.1016/j.bbrc. 2009.06.153.
44. Xu GL, Pan YK, Wang BY, Huang L, Tian L, Xue JL, et al. TTRAP is a novel PML nuclear bodies-associated protein. Biochem Biophys Res Commun 2008; 375:395-8; PMID:18706885; DOI:10.1016/j. bbrc.2008.08.023.
45. van Damme E, Laukens K, Dang TH, van Ostade X. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 2010; 6:51-67; PMID:20087442.
46. Saffert RT, Kalejta RF. Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices or both? Future Virol 2008; 3:265-77; PMID:19763230; DOI:10.2217/17460794.3.3.265.
47. Lallemand-Breitenbach V, De The H. PML nuclear bodies. Cold Spring Harb Perspect Biol 2010; 2: 661; PMID:20452955; DOI:10.1101/cshperspect. a000661.
48. Salomoni P. Stemming out of a new PML era? Cell Death Differ 2009; 16:1083-92; PMID:19521423; DOI:10.1038/cdd.2009.63.
49. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007; 89:819-30; PMID:17343971; DOI:10.1016/j. biochi.2007.01.004.
50. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, De The H, Chelbi-Alix MK. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 2001; 20:3495-505; PMID:11432836; DOI:10.1093/emboj/20.13.3495.
51. Schier AF. Nodal morphogens. Cold Spring Harb Perspect Biol 2009; 1:3459; PMID:20066122; DOI:10.1101/cshperspect.a003459.
52. Micalizzi DS, Farabaugh SM, Ford HL. Epithelialmesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15:117-34; PMID:20490631; DOI:10.1007/s10911-010- 9178-9.
53. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; DOI:10.1016/j.cell.2011.02.013.
54. Zhang ZB, Hu J, Bi YY, Zhao ZW, Tao N, Yan H, et al. [Effect of TTRAP expression on apoptosis induced by hydroquinone in HL-60 cells in vitro]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2007; 25:654-6.
55. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231:509-13; PMID:9070310; DOI:10.1006/bbrc.1997.6132.
56. Lee HY, Youn SW, Kim JY, Park KW, Hwang CI, Park WY, et al. FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-terminal kinase and NFkappaB. Arterioscler Thromb Vasc Biol 2008; 28:112-20; PMID:18032780; DOI:10.1161/ATVBAHA.107.153304.
57. Bachman KE, Park BH. Duel nature of TGFbeta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 2005; 17:49-54; PMID:15608513; DOI:10.1097/01.cco.0000143682.45316.ae.
58. Tian M, Schiemann WP. The TGFbeta paradox in human cancer: an update. Future Oncol 2009; 5:259-71; PMID:19284383; DOI:10.2217/14796694.5.2.259.
59. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008; 29:1275-88; PMID:18954521; DOI:10.1111/j.1745-7254.2008. 00889.x.
60. O'Donnell MA, Ting AT. Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling. Cell Cycle 2010; 9:1065-71; PMID:20237426; DOI:10.4161/cc.9.6.10982.
61. Shirley S, Micheau O. The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death? Oncotarget 2010; 1:317-9; PMID:21307398.
62. Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359-66; PMID:21307400.
63. Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, et al. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS ONE 2008; 3:3534; PMID:18953412; DOI:10.1371/journal.pone.0003534.
64. Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 2006; 131:925-33; PMID:16952561; DOI:10.1053/j. gastro.2006.04.026.
65. Pyeon D, Newton MA, Lambert PF, Den Boon JA, Sengupta S, Marsit CJ, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67:4605-19; PMID:17510386; DOI:10.1158/0008-5472.CAN- 06-3619.
66. Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23:2129-38; PMID:19657361; DOI:10.1038/leu. 2009.161.
67. Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE 2009; 4:5645; PMID:19461970; DOI:10.1371/journal.pone. 0005645.
68. Galamb O, Spisak S, Sipos F, Toth K, Solymosi N, Wichmann B, et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer 2010; 102:765-73; PMID:20087348; DOI:10.1038/sj.bjc.6605515.
69. Sabates-Bellver J, van der Flier LG, De Palo M, Cattaneo E, Maake C, Rehrauer H, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007; 5:1263-75; PMID:18171984; DOI:10.1158/1541-7786.MCR-07-0267.
70. Vahteristo P, Kokko A, Saksela O, Aittomaki K, Aaltonen LA. Blood-derived gene-expression profiling in unravelling susceptibility to recessive disease. J Med Genet 2007; 44:718-20; PMID:17660462; DOI:10.1136/jmg.2007.051342.
71. Tuduri S, Crabbe L, Tourriere H, Coquelle A, Pasero P. Does interference between replication and transcription contribute to genomic instability in cancer cells? Cell Cycle 2010; 9:1886-92; PMID:20495385; DOI:10.4161/cc.9.10. 11539.
72. Sordet O, Nakamura AJ, Redon CE, Pommier Y. DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. Cell Cycle 2010; 9:274-8; PMID:20023421; DOI:10.4161/cc.9.2.10506.
73. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138:958-68; PMID:19914252; DOI:10.1053/j.gastro. 2009.11.005.
74. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons- Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7:64; PMID:17430594; DOI:10.1186/1471-2407-7-64.
75. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9:338-50; PMID:19377506; DOI:10.1038/nrc2607.
76. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002; 38:217-27; PMID:12445742; DOI:10.1016/S0169-5002(02)00224-6.
77. Rünger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine or etoposide. J Invest Dermatol 2000; 114:34-9; PMID:10620112; DOI:10.1046/j.1523- 747.2000.00844.x.
78. Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010; 1:606-19; PMID:21317456.
79. McCandliss BD, Noble KG. The development of reading impairment: a cognitive neuroscience model. Ment Retard Dev Disabil Res Rev 2003; 9:196-204; PMID:12953299; DOI:10.1002/mrdd.10080.
80. Gabel LA, Gibson CJ, Gruen JR, LoTurco JJ. Progress towards a cellular neurobiology of reading disability. Neurobiol Dis 2010; 38:173-80; PMID:19616627; DOI:10.1016/j.nbd.2009.06.019.
81. Kaplan DE, Gayan J, Ahn J, Won TW, Pauls D, Olson RK, et al. Evidence for linkage and association with reading disability on 6p21.3-22. Am J Hum Genet 2002; 70:1287-98; PMID:11951179; DOI:10.1086/340449.
82. Gayán J, Olson RK. Reading disability: evidence for a genetic etiology. Eur Child Adolesc Psychiatry 1999; 8:52-5; PMID:10638371; DOI:10.1007/PL00010695.
83. Cardon LR, Smith SD, Fulker DW, Kimberling WJ, Pennington BF, DeFries JC. Quantitative trait locus for reading disability on chromosome 6. Science 1994; 266:276-9; PMID:7939663; DOI:10.1126/science. 7939663.
84. Grigorenko EL, Wood FB, Meyer MS, Hart LA, Speed WC, Shuster A, et al. Susceptibility loci for distinct components of developmental dyslexia on chromosomes 6 and 15. Am J Hum Genet 1997; 60:27-39; PMID:8981944.
85. Fisher SE, Marlow AJ, Lamb J, Maestrini E, Williams DF, Richardson AJ, et al. A quantitative-trait locus on chromosome 6p influences different aspects of developmental dyslexia. Am J Hum Genet 1999; 64:146-56; PMID:9915953; DOI:10.1086/302190.
86. Gayán J, Smith SD, Cherny SS, Cardon LR, Fulker DW, Brower AM, et al. Quantitative-trait locus for specific language and reading deficits on chromosome 6p. Am J Hum Genet 1999; 64:157-64; PMID:9915954; DOI:10.1086/302191.
87. Grigorenko EL, Wood FB, Meyer MS, Pauls DL. Chromosome 6p influences on different dyslexia-related cognitive processes: further confirmation. Am J Hum Genet 2000; 66:715-23; PMID:10677331; DOI:10.1086/302755.
88. Francks C, Paracchini S, Smith SD, Richardson AJ, Scerri TS, Cardon LR, et al. A 77-kilobase region of chromosome 6p22.2 is associated with dyslexia in families from the United Kingdom and from the United States. Am J Hum Genet 2004; 75:1046-58; PMID:15514892; DOI:10.1086/426404.
89. Deffenbacher KE, Kenyon JB, Hoover DM, Olson RK, Pennington BF, DeFries JC, et al. Refinement of the 6p21.3 quantitative trait locus influencing dyslexia: linkage and association analyses. Hum Genet 2004; 115:128-38; PMID:15138886; DOI:10.1007/s00439-004-1126-6.
90. Cope N, Harold D, Hill G, Moskvina V, Stevenson J, Holmans P, et al. Strong evidence that KIAA0319 on chromosome 6p is a susceptibility gene for developmental dyslexia. Am J Hum Genet 2005; 76:581-91; PMID:15717286; DOI:10.1086/429131.
91. Luciano M, Lind PA, Duffy DL, Castles A, Wright MJ, Montgomery GW, et al. A haplotype spanning KIAA0319 and TTRAP is associated with normal variation in reading and spelling ability. Biol Psychiatry 2007; 62:811-7; PMID:17597587; DOI:10.1016/j. biopsych.2007.03.007.
92. Paracchini S, Thomas A, Castro S, Lai C, Paramasivam M, Wang Y, et al. The chromosome 6p22 haplotype associated with dyslexia reduces the expression of KIAA0319, a novel gene involved in neuronal migration. Hum Mol Genet 2006; 15:1659-66; PMID:16600991; DOI:10.1093/hmg/ddl089.
93. Harold D, Paracchini S, Scerri T, Dennis M, Cope N, Hill G, et al. Further evidence that the KIAA0319 gene confers susceptibility to developmental dyslexia. Mol Psychiatry 2006; 11:1085-91. (Pubitemid 44863433)
94. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299:256-9; PMID:12446870; DOI:10.1126/science. 1077209.
95. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8:519-29; PMID:17565364; DOI:10.1038/nrm2199.
96. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74:739- 89; PMID:15952902; DOI:10.1146/annurev.biochem. 73.011303.074134.
97. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005; 6:11-22; PMID:15611723; DOI:10.1038/nrn1587.
98. Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 2009; 14:455-68; PMID:19130231; DOI:10.1007/s10495- 008-0301-y.
99. Gregersen N, Bolund L, Bross P. Protein misfolding, aggregation and degradation in disease. Mol Biotechnol 2005; 31:141-50; PMID:16170215; DOI:10.1385/MB:31:2:141.
100. Lin JH, Walter P, Yen TS. Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol 2008; 3:399-425; PMID:18039139; DOI:10.1146/annurev. pathmechdis.3.121806.151434.
101. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006; 441:173-8; PMID:16688168.
102. Ramsey SA, Klemm SL, Zak DE, Kennedy KA, Thorsson V, Li B, et al. Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. PLOS Comput Biol 2008; 4:1000021; PMID:18369420; DOI:10.1371/journal.pcbi.1000021.
103. Carlson BA, Yoo MH, Sano Y, Sengupta A, Kim JY, Irons R, et al. Selenoproteins regulate macrophage invasiveness and extracellular matrix-related gene expression. BMC Immunol 2009; 10:57; PMID:19863805; DOI:10.1186/1471-2172- 10-57.
104. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42:145-51; PMID:18304834; DOI:10.1016/j.cyto.2008.01.006.
105. Ose R, Yanagawa T, Ikeda S, Ohara O, Koga H. PCDH24-induced contact inhibition involves downregulation of beta-catenin signaling. Mol Oncol 2009; 3:54-66; PMID:19383367; DOI:10.1016/j. molonc.2008.10.005.
106. Ekeowa UI, Marciniak SJ, Lomas DA. alpha(1)- antitrypsin deficiency and inflammation. Expert Rev Clin Immunol 2011; 7:243-52; PMID:21426261; DOI:10.1586/eci.10.95.
107. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrateresistant prostate cancer. Cancer Res 2009; 69:958-66; PMID:19176386; DOI:10.1158/0008-5472.CAN-08-2216.
108. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113:2375-85; PMID:19056693; DOI:10.1182/blood-2007- 09-113597.
109. Liu F, Lei W, O'Rourke JP, Ness SA. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. Oncogene 2006; 25:795- 805; PMID:16205643; DOI:10.1038/sj.onc.1209105.
110. Lei W, Rushton JJ, Davis LM, Liu F, Ness SA. Positive and negative determinants of target gene specificity in myb transcription factors. J Biol Chem 2004; 279:29519-27; PMID:15105423; DOI:10.1074/jbc. M403133200.
111. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, et al. Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 2009; 10:1026-33; PMID:19668219; DOI:10.1038/ni.1773.
112. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, et al. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res 2009; 69:1368-74; PMID:19190338; DOI:10.1158/0008-5472.CAN-08-2742.
113. Hansen W, Westendorf AM, Reinwald S, Bruder D, Deppenmeier S, Groebe L, et al. Chronic antigen stimulation in vivo induces a distinct population of antigen-specific Foxp3 CD25 regulatory T cells. J Immunol 2007; 179:8059-68; PMID:18056346.
114. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178:2229-40; PMID:17277128.
115. Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL. Innate immune responses to TREM-1 activation: overlap, divergence and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008; 180:3520-34; PMID:18292579.
116. Szatmari I, Torocsik D, Agostini M, Nagy T, Gurnell M, Barta E, et al. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007; 110:3271-80; PMID:17664351; DOI:10.1182/blood- 2007-06-096222.
117. Rome S, Clement K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, et al. Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem 2003; 278:18063-8; PMID:12621037; DOI:10.1074/jbc.M300293200.
118. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, et al. SIRT6 links histone H3 lysine 9 deacetylation to NFkappaB-dependent gene expression and organismal life span. Cell 2009; 136:62-74; PMID:19135889; DOI:10.1016/j.cell.2008.10.052.
119. Hidvegi T, Mirnics K, Hale P, Ewing M, Beckett C, Perlmutter DH. Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem 2007; 282:27769-80; PMID:17635928; DOI:10.1074/jbc.M704330200.
120. Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE. The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway. Nucleic Acids Res 2007; 35:4542-51; PMID:17586820; DOI:10.1093/nar/gkm461.